Sumitomo Pharma | Sustainability Performance
Develops and markets pharmaceutical products.
1897
Japan
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$100M - 500M in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5943
Overallⓘ#286
in Japanⓘ#140
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Financial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- Sumitomo Pharma Co Ltd (formerly Sumitomo Dainippon Pharma), Japanese pharma major, has faced multiple US class actions over alleged inadequate disclosure of Latuda generic competition affecting Sumitomo Pharma's US revenue, plus the contested 2024 USD 800+ million Myovant Sciences acquisition integration challenges and sustained share price collapse affecting Japanese institutional shareholders.
